The Filing Desk

4D Molecular Therapeutics vs Recursion Pharmaceuticals

4D Molecular Therapeutics FDMT · Recursion Pharmaceuticals RXRX · Biotechnology

4D Molecular Therapeutics reported revenue of $85 million in fiscal 2025, about the same as Recursion Pharmaceuticals' $75 million in fiscal 2025. 4D Molecular Therapeutics' revenue grew 230194.6% in its latest year, and Recursion Pharmaceuticals' grew 26.9%. 4D Molecular Therapeutics had an operating margin of -187.2%, against -867.9% at Recursion Pharmaceuticals. Free cash flow was −$110 million at 4D Molecular Therapeutics and −$378 million at Recursion Pharmaceuticals.

Side by side

4D Molecular TherapeuticsRecursion Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$85M$75M
Revenue growth230,194.6%26.9%
Revenue growth a year, last 5 years44.3%79.6%
Gross margin—5.0%
Operating margin−187.2%−867.9%
Net margin−164.4%−863.4%
Free cash flow−$110M−$378M
Free cash flow margin−128.7%−506.5%
Return on capital—−117.2%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count7.4%63.2%
Last close$12.23$3.19
P/E at the last close——
Insider trades, last 12 months—sold $7.1 million
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
4D Molecular TherapeuticsRecursion Pharmaceuticals
Operating margin
Percent of revenue
4D Molecular TherapeuticsRecursion Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
4D Molecular TherapeuticsRecursion Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the 4D Molecular Therapeutics and Recursion Pharmaceuticals pages.